Linzagolix (Yselty) with hormonal add-back therapy will offer a new at-home treatment option for some women in England with ...

Women living with fibroids in Kenya now have access to a promising new treatment option. High-Intensity Focused Ultrasound ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases ...